T. Rowe Price Investment Management’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $25K | Buy |
+509
| New | +$25K | ﹤0.01% | 669 |
|
|
2024
Q2 | – | Sell |
-1,095,101
| Closed | -$55M | – | 646 |
|
|
2024
Q1 | $55M | Sell |
1,095,101
-125,501
| -10% | -$6.3M | 0.03% | 377 |
|
|
2023
Q4 | $73.7M | Buy |
1,220,602
+5,879
| +0.5% | +$355K | 0.05% | 325 |
|
|
2023
Q3 | $69.2M | Buy |
1,214,723
+65,914
| +6% | +$3.76M | 0.05% | 312 |
|
|
2023
Q2 | $58.6M | Buy |
+1,148,809
| New | +$58.6M | 0.04% | 354 |
|